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Abstract
From a critical analysis of medicalization studies, and 
as a contribution to these perspectives, we describe 
and analyze the ways in which the transnational phar-
maceutical industry penetrates diverse social spaces, 
with different marketing strategies, to consolidate 
medicalized processes in Argentina and Brazil. We 
analyzed two expansion methods of medicalization 
processes and specific ADHD diagnostic and treatment 
aspects and trends were developed in both countries: 
the impact of the pharmaceutical industry on advocacy 
groups in Brazil and pharmaceutical marketing strate-
gies aimed at non-medical actors in Argentina. These 
two methods are characterized by involving other ac-
tors than medical professionals. The methodology in-
cludes data from research conducted in Argentina and 
Brazil between 1998 and 2014, based in the University 
of Buenos Aires and in the State University of Rio de 
Janeiro, focused on the study of ADHD diagnostic and 
treatment processes and methylphenidate consump-
tion in both countries. We used individual and group 
semi-structured interview techniques with professors 
and health professionals, official and professional or-
ganization statistics, and national and international 
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general and specialized literature. We concluded that 
the phenomena documented in Argentina and Brazil 
highlight the importance of conducting investigations 
that covers specific aspects of empirical cases and 
their multiple connections with broader and intense 
knowledges networks, dispositives, normatives and ac-
tors involved in the medicalization in the 21st century. 
Keywords: Medicalization; Pharmaceutical Indus-
try; Advocacy Groups; ADHD; Argentina; Brazil.
Resumen
Desde un análisis crítico de los estudios de la medi-
calización, y como un aporte a estas perspectivas, 
describimos y analizamos los modos en que la indus-
tria farmacéutica transnacional penetra en diversos 
espacios sociales, con diferentes estrategias de mar-
keting, interviniendo en la consolidación de procesos 
medicalizadores en Argentina y Brasil. Se analizan 
dos modalidades de expansión de los procesos de 
medicalización, y se desarrollan aspectos y tenden-
cias específicas del diagnóstico y tratamiento del 
TDAH en ambos países: la incidencia de la industria 
farmacéutica en los grupos de apoyo en Brasil y las 
estrategias de marketing farmacéutico orientadas 
a actores no médicos en Argentina. Estas dos mo-
dalidades se caracterizan por no involucrar sólo al 
profesional médico. La metodología incluye datos de 
investigaciones conducidas en Argentina y Brasil en-
tre 1998 y 2014, con sede en la Universidad de Buenos 
Aires y la Universidade Estadual do Rio de Janeiro, 
orientadas al estudio de los procesos de diagnóstico y 
tratamiento del TDAH y el consumo de metilfenidato 
en ambos países. Se emplearon técnicas de entrevista 
semiestructurada individual y grupal a profesores 
y profesionales de salud, estadísticas oficiales y de 
organizaciones profesionales, y revisión de bibliogra-
fía general y especializada nacional e internacional. 
Concluimos que los fenómenos documentados en 
Argentina y Brasil ponen de relieve la importancia 
de efectuar investigaciones que contemplen aspectos 
singulares de los casos empíricos, y sus múltiples 
vinculaciones con entramados más amplios y en 
tensión de saberes, dispositivos, normativas y actores 
involucrados en la medicalización en el siglo XXI.
Palabras clave: Medicalización; Industria Farma-
céutica; Grupos de Apoyo; TDAH; Argentina; Brasil..
Introduction
The perspective of the medicalization criticism 
has more than half a century (Clarke; Shim, 2011). 
Its original definition associated with the expan-
sion of the medical domain has been reconfigured, 
currently covering a complex space of intelligibility 
that includes the definition, description, under-
standing, and treatment of a problem in medical 
terms (Conrad, 2007, 2013). Initially focused on phy-
sicians, social movements and inter-professional 
organizations, nowadays, it also targets the trans-
national pharmaceutical industry, biotechnology, 
internet, health markets, and consumers (Conrad, 
2005, 2013). These elements reinforce the position 
of authors, such as Lupton (1997), who supports 
the thesis that the asymmetry between the medi-
cal power and patient power is no longer enough 
to understand the issues involving contemporary 
medicalizing processes.
At the same time, the problems related to the 
attention deficit hyperactivity disorder (hereinafter 
ADHD) have aroused the interest of different social 
thinking frameworks. The line of analysis of the 
society’s medicalization processes represented by 
Conrad and his colleagues, in particular, has been 
developing an analysis of ADHD as a paradigmatic 
example of such processes and transformations for 
40 years (Conrad, 1975; Conrad; Schneider, 1992; 
Conrad; Potter, 2003; Conrad; Bergey, 2014).
In the most recent analysis of the globalization 
of ADHD conducted by Conrad and Bergey (2014), a 
series of mechanisms that contribute to the posi-
tioning of the clinical profile as a global diagnosis 
is marked. In their work, they rank the incidence of 
non-medical actors in the medicalization processes 
of ADHD in the 21st century and emphasize the need 
to meet different national cases to understand the 
migration of the diagnosis of ADHD outside the 
United States.
From a critical analysis of medicalization stud-
ies, and as a contribution to these perspectives, we 
present herein results of researches conducted in 
Argentina and Brazil, developing issues and trends 
with their own and specific particularities and nu-
ances of the diagnosis and treatment of ADHD in 
both countries, through the description and analysis 
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of two main methods of expansion of medicalization 
processes, both characterized by involving not only 
the medical professionals, but a range of other so-
cial groups and actors, institutions and dispositives.
The key issue addressed is the ways in which the 
transnational pharmaceutical industry enters vari-
ous social spaces with different marketing strategies, 
so that the different groups and actors consolidate 
medicalizing processes. Firstly, we want to describe 
and analyze how the pharmaceutical industry influ-
ences ADHD advocacy groups in Brazil and, secondly, 
how it intervenes in Argentina, through other major 
actors in the health and education sectors. On the one 
hand, the two aspects identified and differentiated 
by countries respond to a difference of scope in the 
development of the pharmaceutical marketing in 
both countries and, on the other hand, to the need to 
contribute to the configuration of a panoramic view 
while aspects of a global strategy for both countries 
of the region are documented.
Methodology
The information analyzed comes from the inves-
tigations conducted in Argentina and Brazil. For 
the analysis of pharmaceutical marketing strate-
gies for ADHD in Argentina, we use results of two 
investigations between 2007 and 2014, both based 
at the University of Buenos Aires (UBA). We ana-
lyzed specialized literature both in Argentina and 
worldwide, national articles about the subject, of-
ficial and professional organization statistics, and 
65 individual and group semi-structured interviews 
with health professionals, with clinical, teaching, 
and research attachment in the public sector, with 
social security and private sector professionals. 
Interviews were also conducted with key informants 
and pharmaceutical sales representatives (PSR) of 
the pharmaceutical industry.
Interviews were conducted in two stages: 35 
between October and December 2007, and between 
April and June 2008; and 30 from August 2009 
until March 2011, in four jurisdictions: Salta, Cor-
rientes, Tierra del Fuego, and city of Buenos Aires. 
A non-probabilistic purposive sampling criterion 
was followed. Primary and secondary data obtained 
were processed with analytical and interpretative 
methods, and triangulation methods of sources 
and results.
For the analysis of ADHD advocacy groups in 
Brazil, we assessed results of different studies 
conducted at the State University of Rio de Janeiro 
(UERJ). One of them aimed at the literature analy-
sis on ADHD, hyperactivity, and methylphenidate 
in SciELO and PubMed databases. Another study 
analyzed 103 Brazilian publications, consisting 
of 72 reports in mass-circulation newspapers and 
magazines and 31 articles of journals of Psychiatry 
on the uses of Ritalin®, since 1998 – the year in which 
the drug was authorized in Brazil – until 2008. The 
search was focused on the Brazilian Psychiatry 
journals indexed in SciELO database, as well as 
in newspapers and journals aimed at the public in 
general, with the largest circulation (Itaborahy; 
Ortega, 2013).
Using the semi-structured interview technique 
with 16 individuals, aged 18 or more, who were us-
ers of methylphenidate, a third study focused on 
the analysis of the senses and meanings of the use 
of this psychoactive substance by such individuals 
(Barros, 2014). A fourth study herein analyzed the 
meanings attributed to the diagnosis of ADHD in a 
population of educators, by using participant obser-
vation techniques and semi-structured interviews 
with teachers and health professionals, in a school 
in the city of Niteroi, in the State of Rio de Janeiro 
(Chagas, 2013).
All investigations comply with the national and 
international applicable standards and ethical safe-
guards for studies on human health.
The diagnosis of ADHD and 
the latest characteristics of 
medicalization
With the pioneering studies that analyzed hy-
perkinesis and deviant behavior, the current clas-
sification of ADHD was positioned as an empirical 
example for the theorization of the problem of the 
medicalization of society. Focused on the medical 
institution as a social control agent, Conrad (1975) 
registered his work in the analyses linking the psy-
chiatry and public health to the deviant social be-
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havior, and considers them as social control agents. 
In the following decade, the ADHD (then called 
hyperactivity) was also discussed as an example of 
medicalization of deviance, identifying a series of 
actors that are still related to the current problems, 
which include schools, families, pharmaceutical 
companies and physicians themselves (Conrad, 
1982). Subsequently, the analysis of hyperactivity 
was ranked together with crime and child abuse, as 
examples of the medicalization of childhood. The 
distinctive weighting of childhood lies in the fact 
it is, at the same time, subject to regulations and 
sanctions, and triggers preventive and protection 
actions on behalf of the social group, making it a 
sector of society especially susceptible to be at risk 
of medicalization (Conrad; Schneider, 1992).
ADHD is presented as one of the pioneering di-
agnoses in the use of psychotropic drugs for child 
behavior problems, resulting in extremely high 
profits for the pharmaceutical industry (Conrad, 
2005). However, although initially it was associ-
ated with a primarily childhood condition (CDC, 
2015) and predominantly borders within the United 
States (Faraone et al., 2003), more recently, ADHD 
shows an increase in diagnosis of adults (Conrad; 
Potter, 2003) and an expansion into other countries 
(Polancyk et al., 2007;) Conrad; Bergey, 2014; Singh 
et al., 2013). From the analysis, which understands 
the medicalization is expressed in gradients, ADHD 
in adults is a relevant example to illustrate how the 
psychiatric categories, once established, can expand 
and include new aspects (Conrad; Potter, 2003). Also 
to illustrate how patients acquire health-related in-
formation and incorporate it in their demands and 
criticisms to the health professionals they see. In 
this context, we highlight the incidence of internet 
and advocacy groups in the medicalization today 
(Conrad; Leiter, 2004).
More recently, works about ADHD and medical-
ization that analyze the recreation of the health con-
sumer and the biomedicalization of childhood have 
been published (Iriart; Iglesias Ríos, 2012). ADHD is 
also taken as an example of the changes introduced 
by DSM-5 handbook in the categorizing logic of the 
so-called mental disorders (Bianchi, 2015).
In line with these changes, Conrad and Bergey 
(2014) outlined some features of what they call the 
“impeding globalization of ADHD”, under the ex-
pansion of the category outside the United States. 
They argue that, although the global information 
is sparse, the available data suggest an increase in 
the global prevalence of ADHD diagnosis (Polancyk 
et al., 2007), and an increase in the consumption of 
medication for ADHD in a wide range of countries. 
That is why the analysis of ADHD advocacy groups 
in Brazil and the pharmaceutical marketing strate-
gies about ADHD aimed at parents and teachers in 
Argentina mean a contribution to increase the still 
few studies that show how the diagnosis and treat-
ment of ADHD are migrating to different regions of 
the globe (Conrad; Bergey, 2014; Zorzanelli; Ortega; 
Bezerra, 2014).
Globalized medicalization: 
physicians and beyond them
Although the studies conducted in the 1970s 
ranked among the most important forces of medi-
calization to physicians, social movements and 
interest groups, and some professional or inter-
professional organizations since then to now, the 
medicine has shown significant changes, making 
other formerly underlying forces to contribute to the 
process of medicalization. The most recent perspec-
tive outlined by Conrad to address the problems of 
medicalization has the peculiarity of not focusing 
on the influence of physicians or law reformers, 
nor in medical and scientific discoveries. His con-
tribution is focused on the creation of markets, and 
the impact of those markets in the medicalization 
(Conrad, 2007).
Although the actors involved are similar, the 
emphasis of each is different, and this is the main 
key to understand the characteristics of the medi-
calization of society today. With the changes in the 
medical setting, important areas of medicalization 
are moving from a professional-medical dominance 
to a market dominance (Conrad; Leiter, 2004). 
Linked to the displacement of the central role of 
health professionals is the relevance that, in the 
21st century, acquires the consumption, as a general 
logic with which to approach the problems related to 
medicalization processes. Both Conrad and others 
(Conrad; Leiter, 2004; Conrad, 2013; Conrad; Ber-
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gey, 2014) and Clarke and Shim (2013) and Lupton 
(1997) recognize this displacement and highlight 
the link between the creation of health markets, 
the validity of a growing logic of consumption in 
relation to access to health, and the dominance of 
the transnational pharmaceutical industry, with 
its multiple marketing strategies applied to differ-
ent population segments, as a result of the specific 
psychiatric diagnosis.
Then, we registered two investigated phenom-
ena, which account for the repositioning of medi-
cal professionals and the relevance taken by other 
actors in the medicalization processes of ADHD. 
On the one hand, we highlight the deployment of 
various strategies of pharmaceutical marketing 
for ADHD in Argentina, which are not aimed at the 
physician as the main recipient, and on the other 
hand, its incidence in the advocacy groups in Brazil.
Argentina: the integration between 
old and new actors
In the case of ADHD, associations and advocacy 
groups for patients and families in Argentina do not 
reach the scale or articulation with pharmaceutical 
companies existing in Brazil, United States, and 
European countries.
According to Conrad and Bergey (2014), the phar-
maceutical industry identifies certain countries as 
potential markets for the expansion of ADHD. Some 
market research companies suggest that the global 
market of drugs for ADHD is shrunk because there 
is still no knowledge about the disorder. Facing an 
oversaturated market like the American market, 
so-called emerging markets, such as China, India, 
and Brazil, can contribute to the global growth 
of the pharmaceutical industry in the short term. 
This indicates the need for further marketing and 
advertising campaigns targeted at both physicians 
and potential consumers.
From the analysis on marketing strategies in 
the pharmaceutical industry in Argentina, however, 
we observe a mixture between a physician-oriented 
marketing model (in which the professional is the 
main objective) and a consumer-oriented marketing 
model (which includes family and school) (Bianchi; 
Faraone, 2015).
Although product promotion methods by phar-
maceutical industries involve a range of actors, 
physicians constitute a historical stronghold, and 
are irreplaceable when drugs require prescription 
(Conrad; Leiter, 2004). Besides the well-known 
strategies of incentives and/or controls (Jara, 2007; 
Lakoff, 2004), in Argentina and, with respect to 
ADHD, we also documented the use of healthcare 
professionals such as disseminators of information, 
named as opinion leaders or speakers.
Regarding the first strategy, we found that 
its dynamics has suffered variations regarding 
the classic method of regular visits to the physi-
cian by PSR. In child mental health, we realized 
that PSRs hardly visit pediatricians, and that the 
information about psychoactive drugs circulates 
through publications of laboratories and those so-
called “Consensus Guidelines”. These guidelines 
consist of agreements on the clinical practices to 
follow built from what is known as “available evi-
dence”. This consensus comes from expert meet-
ings, often under the sponsorship of laboratories 
(Gonzalez Pardo; Pérez Álvarez, 2007) and with 
the support of scientific societies. Thus, protocols 
and evidence-based medicine were turned into 
rules to follow and invoke to not be left out of the 
hegemonic scientific consensus (Iriart, 2008). In 
general terms, these publications are aimed at 
child and adolescent psychiatry and child neurol-
ogy; the latter being the most relevant specialty in 
the specific case of ADHD in Argentina (Arizaga 
et al., 2008).
On the other hand, the involvement of opinion 
leaders is so influential that it is incorporated into 
the calculations of profitability of the pharmaceuti-
cal campaigns (Moynihan; Cassels, 2006). The dis-
semination of innovations regarding the diagnos-
tics and therapeutics in scientific meetings, media 
and specialized publications, and the recognition 
of other professionals, position them as relevant 
actors in marketing strategies. In the case of ADHD, 
we highlighted in the sources and interviews that 
opinion leaders are child and adolescent psychia-
trists and child neurologists belonging both to pub-
lic and private institutions, with renowned medical 
reputation in the city of Buenos Aires, and other 
jurisdictions in the country (Faraone et al., 2009).
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Among family-oriented strategies, we registered 
that some laboratories organize groups of two, 
three or more families to provide information about 
ADHD. Referred to as “help desks”, these meetings 
are frequently promoted at schools, and carried out 
in non-medical care areas.
As part of the expansion of objectives of the phar-
maceutical industry, Conrad and Bergey (2014) un-
derline that educators position themselves as other 
non-medical professionals, for whom campaigns are 
intended. In fact, they point out them as potential 
sickness and treatment brokers or disease spotters. 
The school is an outstanding actor in the beginning 
of the derivation circuit and treatment of ADHD, and 
teachers contribute, by filling out questionnaires 
and other instruments in the diagnostic evaluation 
of the clinical picture.
In Argentina, we documented four pharmaceuti-
cal marketing and advertising methods aimed at the 
educational community. The first, also called “help 
desk”, consists of meetings and informative ses-
sions in schools and especially in education offices 
carried out by laboratory sales representatives, and 
sometimes with participation of medical specialists.
The second identified method works through 
the publication of booklets and newsletters aimed 
at teachers. These publications contain advice for 
teachers and detailed information about the drugs 
used in the treatment of ADHD, statistical data 
and general advice for detection of clinical profile 
(Faraone et al., 2010). The third identified method 
is the merchandising distribution in educational 
institutions of the city of Buenos Aires and northern 
area of the province of Buenos Aires, such as school 
supplies with slogans and images of the psycho-
tropic drug, and with the logo of the laboratory. 
Finally, we documented the inclusion in journals for 
teachers and educational psychologists, of articles 
for the dissemination of drugs for the treatment of 
ADHD, sometimes dedicating full issues to the topic. 
Opinion leaders connected to laboratories produc-
ing widespread psychiatric drugs are responsible 
for the authorship of these articles and dossiers.
These methods are not allowed legally in Argen-
tina according to the National Mental Health Law 
26,657, approved in 2010, confronting the medical-
pharmaceutical hegemony and establishing in its 
article 12 that the psychotropic medication must 
only be prescribed for therapeutic purposes, and 
never replace the therapeutic monitoring or spe-
cial care. There is also a regulation in force since 
1964, the Law 16,463, which prohibits any form of 
advertising for medicinal products requiring a phy-
sician’s prescription. Conrad and Bergey (2014) em-
phasize that the existence of restrictive regulations 
of the marketing of psychotropic drugs indicated 
for ADHD discourages the entry of pharmaceuti-
cal companies, and conversely countries such as 
France or Italy, with less robust legal barriers, of-
fer a greater accessibility and attractiveness to the 
pharmaceutical industry.
The analysis of pharmaceutical marketing strat-
egies for ADHD in children in Argentina, however, 
allows questioning these considerations, since the 
existing national regulations, although it includes 
prohibitions, restrictions and a perspective of rights 
for people who are diagnosed with any psychiatric 
condition, has not resulted by itself in a limitation or 
discouragement to pharmaceutical marketing strat-
egies; rather, they have demonstrated a remarkable 
capacity of response, diversifying proposals, actions 
and offers, and consolidating in the different exist-
ing regulatory gaps.
Brazil: the development of 
advocacy groups
As stressed out by Conrad and Bergey (2014), the 
advocacy groups about ADHD, both online and face-
to-face, are common in the United States, bringing 
together different but interested actors, with scopes 
ranging from local presence, in specific cities, to 
international associations. Though in Brazil there 
is not a tradition of movemets of advocacy groups 
to patients, as there is in United States, there are as-
sociations of family and patients with diseases such 
as autism, ADHD, obsessive compulsive disorder, 
which play an important role in the dissemination of 
knowledge about these diseases and in the struggle 
for better conditions of treatment and citizenship 
(Nunes, 2014). In countries such as United States, 
Canada, Australia, and South Africa, some groups 
seek to combat the medical-scientific discourse 
about the pathology and healing from the affirma-
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tion of an identity different from the normative 
standard (Ortega, 2009; Baker, 2011; Orsini; Smith, 
2010; Orsini, 2009), rather than to secure rights and 
social inclusion.
In the case of ADHD in Brazil, among the mem-
bers of the associations of patients and caregivers 
we find, as well as family members and people 
diagnosed, medical professionals and internation-
ally recognized researchers, the latter with a strong 
presence in groups. The best known national group 
is the Brazilian Association of Attention Deficit (As-
sociação Brasileira de Deficit da Atenção - ABDA), 
created in 1999. It is a non-profit organization that 
aims to spread the knowledge about ADHD. Its 
website (www.tdah.org.br) address is published in 
various magazines and scientific journals, and has 
an average of 200 thousand accesses per month.
In addition, the mixed composition of the ABDA 
turns it into an important means of dissemination 
for laymen and professionals, being also respon-
sible for the dissemination of biomedical discourse 
about ADHD in the country, in the form of academic 
research disseminated both on its website and in 
journals aimed at the legitimation of ADHD as an 
organic disorder. On the website of the Association 
is stated that it is sponsored, among other institu-
tions, professional associations, federations and 
national and international companies, by the 
Novartis and Shire Pharmaceuticals, besides the 
annuity paid by the members. In the website of the 
Association, they explain what ADHD is, its causes, 
diagnosis and treatment, as well as to provide advice 
for family members and patients, and disseminate 
activities and considerations of professionals 
working in this field. Among other actions, the 
Association provides training to health and educa-
tion professionals about ADHD, through services 
provided to towns and cities. Professionals and 
researchers also used the virtual space of the ABDA 
to answer questions about the ADHD published in 
non-specialized press, thus expressing opinions 
and positions on the validity or legitimacy of the 
content published.
Through the website of the ABDA, it is also 
possible to identify some of the main Brazilian 
research centers devoted to the study of ADHD, 
reporting them as possible search websites for the 
treatment of patients with the disorder. Some of 
which contained in the webpage are the Attention 
Deficit Study Group (GEDA), associated to the In-
stitute of Psychiatry of the Federal University of 
Rio de Janeiro, located in the southeast of Brazil. 
The group is responsible for much of the research 
published about methylphenidate and ADHD in the 
country, and participates in the Scientific Council 
of the ABDA. Another group is the Attention Deficit/
Hyperactivity Disorders Program (ProDAH) associ-
ated to the School of Medicine of the University of 
Rio Grande do Sul (Famed/UFRGS), located in the 
southern region of the country. Another institution 
appearing on the website is the Santa Casa de Mi-
sericórdia of Rio de Janeiro, a philanthropic hospital 
funded through donations and public financing of 
some hospital services provided to the population. 
Linked to the Hospital das Clínicas of the School 
of Medicine of the University of São Paulo (HC-
FMUSP), there are two programs: one for children 
and teens, called Attention Deficit and Hyperactiv-
ity Disorders Out-patient Facility (ADHDA) and the 
adult-oriented program called Attention Deficit and 
Hyperactivity in Adults Project (PRODATH).
In addition, we documented that the Alcohol 
and Drugs Research Unity (Uniad), associated to 
the Federal University of São Paulo (Unifesp) is in 
force. These research groups receive the sponsor-
ship of several pharmaceutical companies, such as 
Janssen-Cilag, manufacturer of Concerta®, Bristol-
Myers Squibb, Eli Lilly and Novartis, Abbott and 
Astra-Zeneca. They usually have free consulting 
rooms specialized in child psychiatry, and some 
of the professionals of these research centers are 
involved in the Scientific Council of the ABDA, 
making frequent presentations in pharmaceutical 
laboratories. They are also responsible for a signifi-
cant number of publications about methylphenidate 
in the country.
The partnership among the main centers of 
research in that country promote knowledge 
about ADHD to advocacy groups to patients, and 
its partnerships with pharmaceutical companies 
form an important pole for the dissemination 
of the official discourse about the disorder, as 
analyzed by a research conducted at the Insti-
tute of Social Medicine, State University of Rio 
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de Janeiro (Itaborahy; Ortega, 2010). In this re-
search, it was found that the publications in the 
Jornal Brasileiro de Psiquiatria, major specialized 
journal in the country, contain, to a large extent, 
research of GEDA, and that many of them included 
Concerta® drug ads. The conflict of interest re-
garding the treatment of the users was stated in 
them, however in other articles, the financing of 
laboratories was not explained. In addition, we 
documented that the supplement to this same 
journal of the year 2007 was entirely funded 
by a laboratory responsible for manufacturing 
methylphenidate, from articles to propaganda. 
The information gathered leads to consider that 
the financing of pharmaceutical laboratories in 
research carried out in the country about ADHD 
must not be analyzed with a priori criticism about 
the validity of them, since the need for funding 
for the development of complex investigations 
requiring an extensive infrastructure.
However, the direct influence of the presence of 
the pharmaceutical laboratories in support of the 
research and its main researchers demand a need 
for control and evaluation of the process and the 
ethical implications arising from such sponsorship.
Conclusions
Medicalization is not an univocal, homogeneous, 
or general process. As we argued, Conrad is the 
main author who highlights the medicalization as 
a variable process, irregular, and uneven, in func-
tion of its target and its related social group. By 
emphasizing the role of actors outside the medical 
field, such as the activities of the pharmaceutical 
industry, pediatrics, associations for children with 
learning difficulties and the medical journals of the 
1960s, the involvement of a multiplicity of vectors 
in the medicalization process of ADHD was observed 
(Conrad, 1975).
The globalization of ADHD is being configured 
with different characteristics in each country, 
and with the consolidation and differential inser-
tion of actors and links between them. The two 
cases we presented in Argentina and Brazil are 
examples of how these processes are occurring, 
where the medicalization is extended to non-
medical areas.
In Argentina, the impact of the pharmaceutical 
industry expresses its versatility in the mixture 
of marketing strategies, maintaining a focus on 
the physician as the main recipient, which since 
any scientific productions surveyed is considered 
typical of historical moments earlier in the pro-
cess of medicalization of society, and extending 
its insertion towards non-medical actors, with a 
strong influence on the teaching field, and among 
the parents of children diagnosed with ADHD, in 
a movement that has been understood as a char-
acteristic of the medicalization of psychiatric 
diagnosis in the 21st century, and its globalization 
outside the United States and some European 
countries.
A relevant point is that, although in Argentina 
there is a long-standing regulation which restricts 
the advertising of medication, and recent legisla-
tion that fights for the rights of people with mental 
illness, the pharmaceutical industry carried out 
interstitial actions through which it maintains and 
expands its marketing strategies.
In Brazil, it is worth mentioning that the topic 
is gaining ground in recent decades in and out 
of the reach of the academic research, through 
publications and reaction movements to what has 
been termed the medicalization of everyday life 
(Moyses, 2001; Lima, 2005; Caponi, 2009; Figueira; 
Caliman, 2014; Meira, 2012; Zorzanelli; Ortega; 
Bezerra, 2014).
As we stressed, the organization of groups 
of Brazilian patients has substantial support 
from specialized professionals. The ABDA, main 
support group related to the diagnosis of ADHD, 
has among its members the presence of profes-
sionals and researchers of international renown, 
as well as patients and caregivers. This group, 
with presence in different regions of the country, 
disseminates the work of the most important 
research centers in Brazil in relation to the dis-
order. The connections between research centers, 
patient groups and pharmaceutical companies 
constitute a complex network of training and 
dissemination of biomedical knowledge about 
ADHD in Brazil.
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The phenomena documented in Brazil and 
Argentina set the tone of the specificity of local 
configurations that being raised in relation to 
the globalization of ADHD as medicalized diag-
nosis, and highlight the importance of carrying 
out inves¬tigations (including those conducted 
for this article), which can maintain, at the same 
time a rigorous approach to researches conducted 
in other parts of the world, but that address the 
unique aspects in each empirical national case and 
its mul¬tiple connections with wider and always in 
tension frameworks, of knowledges, dispositives, 
normatives and actors involved in the processes of 
medicalization in the 21st century.
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